IE920840A1 - Alkylenedioxyphenyl ether derivatives having anti-ischaemic,¹memory enhancing and anti-convulsive activity - Google Patents
Alkylenedioxyphenyl ether derivatives having anti-ischaemic,¹memory enhancing and anti-convulsive activityInfo
- Publication number
- IE920840A1 IE920840A1 IE920840A IE920840A IE920840A1 IE 920840 A1 IE920840 A1 IE 920840A1 IE 920840 A IE920840 A IE 920840A IE 920840 A IE920840 A IE 920840A IE 920840 A1 IE920840 A1 IE 920840A1
- Authority
- IE
- Ireland
- Prior art keywords
- group
- atoms
- alkyl
- alkenyl
- alkynyl
- Prior art date
Links
- 230000002082 anti-convulsion Effects 0.000 title claims abstract description 11
- 230000002253 anti-ischaemic effect Effects 0.000 title claims abstract description 9
- 150000002170 ethers Chemical class 0.000 title claims description 5
- 230000002708 enhancing effect Effects 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims abstract description 67
- 150000001875 compounds Chemical class 0.000 claims abstract description 58
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 48
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims abstract description 25
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 22
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 22
- 125000003884 phenylalkyl group Chemical group 0.000 claims abstract description 15
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims abstract description 11
- 125000005312 heteroarylalkynyl group Chemical group 0.000 claims abstract description 11
- 125000006413 ring segment Chemical group 0.000 claims abstract description 11
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims abstract description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 8
- 230000006883 memory enhancing effect Effects 0.000 claims abstract description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 8
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract description 7
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 5
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 5
- 239000001257 hydrogen Substances 0.000 claims abstract description 5
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 5
- 239000001301 oxygen Substances 0.000 claims abstract description 5
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 5
- -1 phenylalkenyl Chemical group 0.000 claims abstract description 5
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000005864 Sulphur Substances 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000002947 alkylene group Chemical group 0.000 claims abstract description 3
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims abstract description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 3
- 125000005843 halogen group Chemical group 0.000 claims abstract description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 2
- 239000000203 mixture Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- NTABMUJQZABQGD-UHFFFAOYSA-N dimethylindole red Chemical class CC1(C)C2=CC=CC=C2N(C)\C1=C\C=C\C1=CC=[N+](CCCS([O-])(=O)=O)C2=CC=CC=C12 NTABMUJQZABQGD-UHFFFAOYSA-N 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 230000001771 impaired effect Effects 0.000 claims description 2
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 229910006069 SO3H Inorganic materials 0.000 abstract description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract description 2
- 125000004663 dialkyl amino group Chemical group 0.000 abstract description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 abstract description 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 21
- 239000000243 solution Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- 239000003921 oil Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 239000012259 ether extract Substances 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 235000011152 sodium sulphate Nutrition 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007954 hypoxia Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 4
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 206010043994 Tonic convulsion Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003480 eluent Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 235000009518 sodium iodide Nutrition 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- FQCPVDJMHFREFH-UHFFFAOYSA-N 5-(1-ethoxyethoxy)-1,3-benzodioxole Chemical compound CCOC(C)OC1=CC=C2OCOC2=C1 FQCPVDJMHFREFH-UHFFFAOYSA-N 0.000 description 2
- QBBKUKCEDKHYLE-UHFFFAOYSA-N 5-[(4-propylpiperazin-1-yl)methyl]-1,3-benzodioxol-4-ol Chemical compound C1CN(CCC)CCN1CC1=CC=C(OCO2)C2=C1O QBBKUKCEDKHYLE-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 241000699694 Gerbillinae Species 0.000 description 2
- 238000011785 NMRI mouse Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LUSZGTFNYDARNI-UHFFFAOYSA-N Sesamol Chemical compound OC1=CC=C2OCOC2=C1 LUSZGTFNYDARNI-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000001966 cerebroprotective effect Effects 0.000 description 2
- 239000010779 crude oil Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
- BNDFDFUICRGDLY-UHFFFAOYSA-N 1-[[5-(1-ethoxyethoxy)-1,3-benzodioxol-4-yl]methyl]-4-methylpiperazine Chemical compound CCOC(C)OC1=CC=C2OCOC2=C1CN1CCN(C)CC1 BNDFDFUICRGDLY-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- FWGSCKIXPFHZIO-UHFFFAOYSA-N 1-methyl-4-[[5-(3-phenylpropoxy)-1,3-benzodioxol-4-yl]methyl]piperazine Chemical compound C1CN(C)CCN1CC1=C(OCO2)C2=CC=C1OCCCC1=CC=CC=C1 FWGSCKIXPFHZIO-UHFFFAOYSA-N 0.000 description 1
- QLEIDMAURCRVCX-UHFFFAOYSA-N 1-propylpiperazine Chemical compound CCCN1CCNCC1 QLEIDMAURCRVCX-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- XMZQWZJMTBCUFT-UHFFFAOYSA-N 3-bromopropylbenzene Chemical compound BrCCCC1=CC=CC=C1 XMZQWZJMTBCUFT-UHFFFAOYSA-N 0.000 description 1
- DIRAULVWNVQFRL-UHFFFAOYSA-N 4-[(4-methylpiperazin-1-yl)methyl]-1,3-benzodioxol-5-ol Chemical compound C1CN(C)CCN1CC1=C(OCO2)C2=CC=C1O DIRAULVWNVQFRL-UHFFFAOYSA-N 0.000 description 1
- HQHMYMINMCVYMC-UHFFFAOYSA-N 4-[[5-(piperidin-4-ylamino)-1,3-dihydroisoindol-2-yl]sulfonyl]benzene-1,3-diol Chemical compound Oc1ccc(c(O)c1)S(=O)(=O)N1Cc2ccc(NC3CCNCC3)cc2C1 HQHMYMINMCVYMC-UHFFFAOYSA-N 0.000 description 1
- DYIKPGTXHNAAKZ-UHFFFAOYSA-N 5-(1-ethoxyethoxy)-1,3-benzodioxole-4-carbaldehyde Chemical compound CCOC(C)OC1=CC=C2OCOC2=C1C=O DYIKPGTXHNAAKZ-UHFFFAOYSA-N 0.000 description 1
- GPABMZXQPPGMAV-UHFFFAOYSA-N 5-(methoxymethoxy)-1,3-benzodioxole Chemical compound COCOC1=CC=C2OCOC2=C1 GPABMZXQPPGMAV-UHFFFAOYSA-N 0.000 description 1
- HRRCQDNTWCSUMO-UHFFFAOYSA-N 5-(methoxymethoxy)-1,3-benzodioxole-2-carbaldehyde Chemical compound C(=O)C1OC2=C(O1)C=CC(=C2)OCOC HRRCQDNTWCSUMO-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 238000006683 Mannich reaction Methods 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CWRVKFFCRWGWCS-UHFFFAOYSA-N Pentrazole Chemical compound C1CCCCC2=NN=NN21 CWRVKFFCRWGWCS-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FVECELJHCSPHKY-WTFKENEKSA-N Veratrine (amorphous) Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@]2(O)O[C@@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-WTFKENEKSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- UWGBIKPRXRSRNM-UHFFFAOYSA-N cevadine Natural products CC=C(C)/C(=O)OC1CCC2(C)C3CCC4C5(O)CC(O)C6(O)C(CN7CC(C)CCC7C6(C)O)C5(O)CC24OCC13O UWGBIKPRXRSRNM-UHFFFAOYSA-N 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 230000001146 hypoxic effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000006263 metalation reaction Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229960005152 pentetrazol Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- MLGCXEBRWGEOQX-UHFFFAOYSA-N tetradifon Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)C1=CC(Cl)=C(Cl)C=C1Cl MLGCXEBRWGEOQX-UHFFFAOYSA-N 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention relates to compounds having anti-ischaemic activity, memory enhancing activity and anti-convulsive activity of the formulae 1 A and 1 B wherein -R, + R2 together form an alkylene group having 1-3 C-atoms which may be substituted with one or more alkyl group(s) having 1- 3 C-atoms; -Z is methylene optionally substituted with one alkyl group having 1-3 C-atoms, or with one phenylalkyl group with 1-3 C-atoms in the alkyl group, which phenyl group may be substituted with a group (Re)p wherein Re is halogen, hydroxy, alkyl or hydroxyalkyl having 1-5 C-atoms, alkoxy having 1-3 C-atoms, S-alkyl, S(O)-alkyl or S(O)2-alkyl having 1-3 Catoms, amino, mono- or dialkylamino having 1-3 C-atoms per alkyl group, trifluoromethyl, trifluoromethoxy, a sulphonylamido group SO2NHR or a carbalkoxy group COOR wherein R is alkyl having 1-4 C-atoms, the group COOH, SO3H,CONH2, the amidino group or cyano group, and p has the value 0-3; -R3 and R4 independent of each other represent hydrogen, alkyl having 1-10 C-atoms, alkenyl or alkynyl having 3-10 Catoms, cycloalkyl having 3-8 C-atoms, cycloalkyl-alkyl having 3-8 ring atoms and 1-5 C-atoms in the alkyl group, phenylalkyl or heteroaryl-alkyl having 1-5 C-atoms in the alkyl group, phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl group having 3-5 C-atoms in the alkenyl group or alkynyl group, which groups R3 and R4 may be substituted with a group (Re)p wherein Re and p have the above mentioned meanings, or wherein R3+R4 together wthe nitrogen atom form a saturated or unsaturated heterocyclic group of 5-7 ring atoms, which may contain a second hetero-atom from the group consisting of oxygen, sulphur and nitrogen, which ring may be substituted with a 5 group (R6)p wherein R6 and p have the above mentioned meanings, or with phenylalkyl, heteroarylalkyl.phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl having at most 3 C-atoms in the alkyl, alkenyl or alkynyl part, which groups may ba substituted with a group (Re)p wherein R6 and 10 p have the above-mentioned meanings, or which ring may be annelated with a phenyl group; -R5 is alkyl having 1-12 C-atoms, alkenyl or alkynyl having 3-12 C-atoms, cycloalkyl having 3-8 C-atoms, cycloalkyl-alkyl having 3-8 ring atoms and 1-5 C-atoms in the alkyl group, 15 phenylalkyl or heteroaryl-alkyl having 1-5 C-atoms in the alkyl sub-group, phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl having 3-5 C-atoms in the alkenyl subgroup or alkynyl sub-group, which groups may be substituted with a group (Re)p, wherein Re and p have the above- 20 mentioned meanings, and which alkyl sub-groups, alkenyl sub-groups and alkynyl sub-groups may contain a group -0-, - - S- or CO, or a pharmacologically acceptable salt thereof.
Description
DIR 0482 the nitrogen atom form a saturated or unsaturated heterocyclic group of 5-7 ring atoms, which may contain a second hetero-atom from the group consisting of oxygen, sulphur and nitrogen, which ring may be substituted with a group (R6)p wherein R6 and p have the above mentioned meanings, or with phenylalkyl, heteroarylalkyl.phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl having at most 3 C-atoms in the alkyl, alkenyl or alkynyl part, which groups may ba substituted with a group (Re)p wherein R6 and p have the above-mentioned meanings, or which ring may be annelated with a phenyl group; -R5 is alkyl having 1-12 C-atoms, alkenyl or alkynyl having 3-12 C-atoms, cycloalkyl having 3-8 C-atoms, cycloalkyl-alkyl having 3-8 ring atoms and 1-5 C-atoms in the alkyl group, phenylalkyl or heteroaryl-alkyl having 1-5 C-atoms in the alkyl sub-group, phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl having 3-5 C-atoms in the alkenyl subgroup or alkynyl sub-group, which groups may be substituted with a group (Re)p, wherein Re and p have the above20 mentioned meanings, and which alkyl sub-groups, alkenyl sub-groups and alkynyl sub-groups may contain a group -0-, - S- or CO, or a pharmacologically acceptable salt thereof.
PATENTS ACT 1964 COMPLETE SPECIFICATION ALKYLENEDIOXYPHENYL ETHER DERIVATIVES HAVING ANTI-ISCHAEMIC, MEMORY ENHANCING AND ANTI-CONVULSIVE ACTIVITY1' 5 , r H-· - it) ί i·«.·„. rr i a.. . b APPLK'ATiOA -4 SPLCinCATION FtlEOJ£..|^L3&£ DUPHAR INTERNATIONAL RESEARCH B.V., a limited liability company duly organised and existing under the laws of the Kingdom of the Netherlands, of C.J. van Houtenlaan 36, Weesp, The Netherlands 5015 DIR 0482 Alkylenedioxyphenyl ether derivatives having anti-ischaemic, memory enhancing and anti-convulsive activity The invention relates to a group of new alkylenedioxyphenyl ether derivatives having 5 interesting anti-ischaemic activity, memory enhancing activity and anti-convulsive activity, to a method of preparing said compounds, and to pharmaceutical compositions comprising at least one of these compounds as the active component.
There is an increasing clinical interest in an effective pharmalogical symptomatic treatment for cerebral and peripheral ischaemic diseases. In patients suffering from these diseases the impaired blood supply causes an inadequate delivery of oxygen and other nutrients to the tissue as well as a diminished removal of metabolic waste products resulting in structural injury and functional deterioration.
Anti-convulsive compounds can be useful in the treatment of epilepsy.
The object of the present invention is to provide active compounds with antiischaemic, memory enhancing and anti-convulsive properties.
It has been found surprisingly that compounds of formulae 1A and 1 B (1A) (IB) wherein -R, + R2 together form an alkylene group having 1-3 C-atoms which may be substituted with one or more alkyl group(s) having 1 -3 C-atoms; -Z is methylene optionally substituted with one alkyl group having 1 -3 C-atoms, or with one phenylalkyl group with 1-3 C-atoms in the alkyl group, which phenyl group may be substituted with a group (R6)p wherein R6 is halogen, hydroxy, alkyl or hydroxyalkyl having 1-5 C-atoms, alkoxy having 1-3 Catoms, S-alkyl, S(O)-alkyl or S(O)2-alkyl having 1-3 C-atoms, amino, mono- or dialkylamino having 1-3 C-atoms per alkyl group, trifluoromethyl, trifluoromethoxy, a sulphonylamido group SO2NHR or a carbalkoxy group COOR wherein R is alkyl having 1 -4 C-atoms, the group COOH, SO3H, CONH2, DIR 0482 the amidino group or cyano group, and p has the value 0-3; -R3 and R4 independent of each other represent hydrogen, alkyl having 1-10 Catoms, alkenyl or alkynyl having 3-10 C-atoms, cycloalkyl having 3-8 C-atoms, cycloalkyl-alkyl having 3-8 ring atoms and 1-5 C-atoms in the alkyl group, phenylalkyl or heteroaryl-alkyl having 1-5 C-atoms in the alkyl group, phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl group having 3-5 C-atoms in the alkenyl group or alkynyl group, which groups R3 and R4 may be substituted with a group (Re)p wherein Re and p have the above mentioned meanings, or wherein R3 + R4 together with the nitrogen atom form a saturated or unsaturated heterocyclic group of 5-7 ring atoms, which may contain a second hetero-atom from the group consisting of oxygen, sulphur and nitrogen, which ring may be substituted with a group (Re)p wherein Re and p have the above mentioned meanings, or with phenylalkyl, heteroaryl-alkyl, phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl having at most 3 C-atoms in the alkyl, alkenyl or alkynyl part, which groups may be substituted with a group (Re)p wherein Re and p have the above-mentioned meanings, or which ring may be annelated with a phenyl group; -R5 is alkyl having 1-12 C-atoms, alkenyl or alkynyl having 3-12 C-atoms, cycloalkyl having 3-8 C-atoms, cycloalkyl-alkyl having 3-8 ring atoms and 1-5 C-atoms in the alkyl group, phenylalkyl or heteroaryl-alkyl having 1-5 C-atoms in the alkyl sub-group, phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl having 3-5 C-atoms in the alkenyl sub-group or alkynyl subgroup, which groups may be substituted with a group (R6)p, wherein Re and p have the above-mentioned meanings, and which alkyl sub-groups, alkenyl sub25 groups and alkynyl sub-groups may contain a group -O-, -S- or CO, prodrugs and pharmaceutically acceptable acid addition salts thereof have interesting and valuable anti-ischaemic, memory enhancing and anti-convulsive properties.
Prodrugs are derivatives of these compounds which as such are inactive, from which, after splitting off an easily removable group, for example an ester group or an ether group, an active compound of formula 1A or 1B is obtained.
Suitable acids with which suitable addition salts can be formed are, for example, hydrochloric acid, sulphuric acid, phosphoric acid, nitric acid, and organic acids like citric acid, fumaric acid, maleic acid, tartaric acid, acetic acid, benzoic acid, p35 toluene sulphonic acid, methane sulphonic acid, etc.
One or more centres of chirality may be present in the compounds having formula DIR 0482 1A or 1B. The invention relates both to racemates and the individual isomers of the compounds having formulae 1A and 1B.
The anti-ischaemic and memory enhancing activity of the compounds has been determined by means of the in vivo hypobaric hypoxia test, the in vitro cardiomyocytes test and the in vivo memory test. These tests were used to characterize substances with cerebro- and/or peripheral-protective activity.
The anti-convulsive activity of the compounds has been determined by means of chemically induced tonic convulsions in vivo. 1) Hypobaric activity in vivo Cerebro-protective activity was determined by measuring the prolongation of the survival time of conscious mice under hypobaric conditions.
Groups of 3 overnight fasted male NMRI mice (15-20 g) are dosed ip (30 mg/kg), 30 minutes before being placed in a chamber at hypobaric pressure of 200 mBar. The prolongation of the survival time is expressed in percentage increase in respiration time, compared to that of the placebo treated control group. 2) Cardiomyocytes in vitro Cyto-protective properties were determined in an in vitro model using isolated 20 calcium tolerant cardiomyocytes according to L. Verdonck et al (Life Sciences, vol.38, (1986) 765-772).
Cardiomyocytes were isolated from male Wistar rat hearts. Rod shaped cells were incubated with the compound to be tested for 30 min. Injury was induced by e.g. veratrine (100zug/ml) or by hypoxia upon which the cells became rounded unless protected by the compound. After 20 min. the remaining rod-shaped cells were counted and the protecting efficacy of the compound was determined. 3) Memory testing under hypoxic conditions Cerebroprotective activity was determined by studying the prevention of hypoxia 30 induced amnesia in gerbils.
In groups of 6-8 gerbils step through passive avoidance was measured after exposure to hypoxia (4% O2, 96% N2) until gasping was observed. Memory testing was performed 4 hrs after drug administration and exposure to hypoxia. 4) Chemically induced tonic convulsions in vivo Protection against pentylene-tetrazole-induced convulsions (50 mg/kg i.v.) was demonstrated in male NMRI-mice, weighing 18-24 g.
DIR 0482 Tonic convulsions were measured 60 minutes after oral administration of the test compound. Suppression of the tonic extensor phase was considered to be the criterion for the anti-convulsive effect. (Purpura D.P., Penry J.K., Tower D.B., Woodburry D.M., Walters R.D. (eds.). Experimental models of epilepsy, Raven Press, New York (1972)).
The compounds having formulae 1A and 1B, wherein the symbols have the abovementioned meaning are new compounds which can be prepared according to methods known per se.
For example compounds having formula 1A can be obtained by first preparing a compound having formula 2 (2) wherein R, and R2 have the above mentioned meaning and wherein R'5 is a so-called directed ortho-metallating group (see for example Acc.Chem.Res., 15, 306 (1982)), such as -CH2OCH3(MOM), -CH(CH3)OC2H5, -CH2O(CH2)2Si(CH3)3(SEM) and the like, via known procedures (see for example, Protective Groups in Organic Chemistry, Ed. J.F.W. McOmie, Plenum Press, London (1973), Chapter 4; Synthesis, 276 (1975); Synthesis 244 (1976); J.Org.Chem., 44, 2480 (1979)), from the corresponding phenolic compounds 2 wherein R'5 is hydrogen. The so-obtained compounds of formula 2 can be converted into the corresponding compounds of formula 3 (3) wherein R7 is hydrogen, alkyl having 1-3 C-atoms, phenylalkyl with 1-3 C-atoms in the alkyl group, which phenyl group may be substituted with a group (Re)p wherein Re and p have the above mentioned meanings, via regioselective deprotonation with DIR 0482 a strong base, for example n-butyllithium and the like, followed by reaction with an electrophile R7-CO-X, wherein X represents a leaving group, for example halogen (see for analogous ortho-directed metallations for example J.Org.Chem., 53, 3936 (1988); J.Heterocyclic Chem., 26, 1827 (1989)).
The so-obtained compounds of formula 3 can be converted into the corresponding compounds of formula 4 (4) by a reductive amination reaction with an amine of the formula R3R4NH, in which formulae R,-R4 and Z have the meanings given in formula 1A, and R'5 and R7 have the meanings given above. This reductive amination reaction can be carried out with a suitable reducing agent such as NaCNBH3 in an inert solvent, for example acetonitrile, or by other reductive amination methods (see for example Russ.Chem.Rev., 49, 14 (1980), or Synthesis, 135 (1975)). In some cases the addition of an acid catalyst may be desirable to enhance the reaction rate.
The so-obtained compounds of formula 4 can be converted into the corresponding compounds of formula 5 (5) in which formula R,-R4 and Z have the meanings given in formula 1 A, by means of an acid-catalyzed removal of R'5.
The so-obtained compounds of formula 5 can be converted into the corresponding compounds of formula 1A wherein R5 has the above mentioned meanings by means of a reaction with a compound of the formula R5-X, wherein X is a so-called leaving group. This reaction is preferably carried out in an inert solvent such as dimethylsulphoxide (DMSO), Ν,Ν-dimethylformamide (DMF) and the like, in the presence of a suitable base such as sodium hydride or potassium tert-butoxide and the like. Sometimes the addition of sodium iodide is desirable. The reaction may be DIR 0482 carried out at somewhat elevated temperatures.
Compounds having general formula 1B can be obtained for example by first preparing a compound having formula 6 wherein RtR4 and Z have the above mentioned meanings, by reacting a compound of the formula 7 OH (7) with a compound of the formula R3R4NH and an aldehyde of the formula R7CHO, in 20 which formulae R,-R4 and R7 have the above mentioned meaning. This so-called Mannich-reaction is preferably carried out in an inert organic solvent, such as ethanol or acetonitrile.
The starting compounds of formula 7 are known or can be obtained analogously to known compounds (see for example W. Baker and R.l. Savage, J.Chem.Soc., 1602 (1938)).
The so-obtained compounds of formula 6 can be converted into the corresponding compounds of formula 1B wherein R5 has the above mentioned meanings in the same manner as described above for the preparation of compounds having formula 1A from compounds having formula 5.
Example I a) 5-(1-ethoxvethoxy)-1,3-benzodioxole A stirred solution of 3,4-methylenedioxyphenol (6.0 g, 43.5 mmol), ethyl vinyl ether 35 (3.75 g, 52.0 mmol) and a catalytic amount of trichloroacetic acid (50 mg, 0.3 mmol) in chloroform (50 ml) was stirred for two hours at room temperature.
Aqueous NaOH (2N, 50 ml) was added and the resulting mixture was extracted with DIR 0482 diethyl ether (3 times). The combined ether extracts were washed with aqueous NaOH (2N) and water, respectively, dried over Na2SO4, filtered and evaporated in vacuo to yield 5-(1-ethoxyethoxy)-1,3-benzodioxole (8.96 g, 98% yield; compound no. 1) as an oil. b) 5-(1 -ethoxvethoxv)-4-f ormyl-1.3-benzodioxole n-Butyllithium (18.6 ml of a 2.5 M solution in hexane, 46.5 mmol) and Ν,Ν,Ν',Ν'tetramethylethylenediamine (5.38 g, 46.3 mmol), respectively, were added (using a syringe) to a stirred solution of 5-(1 -ethoxyethoxy)-1,3-benzodioxole (8.9 g, 42.4 mmol) in dry THF (100 ml) in a nitrogen atmosphere at -78°C. The resulting solution was allowed to attain room temperature and then cooled to -78°C. A solution of Ν,Ν-dimethylformamide (3.70 g, 50.6 mmol) in dry THF (20 ml) was added using a syringe, and the reaction mixture was allowed to attain room temperature. The resulting mixture was quenched with water and extracted with diethyl ether (3 times). The combined ether layers were washed with water (2 times), dried over Na2SO4, filtered and evaporated in vacuo to yield 5-(1ethoxyethoxy)-4-formyl-1,3-benzodioxole (9.7 g, 96% yield; compound no. 2) as a pale yellow solid, m.p. 48-50°C.
In a similar manner 5-methoxymethoxy-1,3-benzodioxole was converted into 420 formyl-5-methoxymethoxy-1,3-benzodioxole (compound no. 3), melting point 8486°C. c) 5-(1-ethoxvethoxv)-4-(4-methvlpiperazinvlmethvl)-1,3-benzodioxole NaCNBH3 (6.4 g, 101.8 mmol) was added to a stirred solution of 5-(125 ethoxyethoxy)-4-formyl-1,3-benzodioxole (16.0 g, 67.2 mmol) and 1methylpiperazine (20.2 g, 201.7 mmol) in CH3CN (150 ml). Acetic acid (10 ml) was added dropwise to the solution in one hour at room temperature, to keep the pH neutral (pH = 7). After 3 hours of additional stirring, most of the CH3CN was evaporated in vacuo. Aqueous NaOH (2N, 300 ml) was added and the resulting mixture was extracted with diethyl ether (3 times). The combined ether extracts were washed with an aqueous solution of Na2CO3, dried over Na2SO4, filtered and evaporated to yield 26 g of a crude oil. This oil was purified by flash chromatography (eluent gradient; dichloromethane/methanol/25% aqueous ammonia = 95/4.5/0.5 to 85/14/1 (v/v)) to give 5-(1-ethoxyethoxy)-4-(4-methyl-piperazinylmethyl)-1,335 benzodioxole (16.0 g, 74% yield, compound no. 4) as a colorless oil.
In a similar manner the compounds of formula 4, wherein R,-R'5 and Z have the meanings indicated in Table A were prepared.
DIR 0482 TABLE A Comp . no . R i + R 2 R3 (+1 Ra R'e z m.p. (°C) 5 -CH,- (CH,)6- -CH(CH3)OC,H6 -CH,- oil 6 -CH,- (CH,),N((CH,),CH3)(CH,),- -CH(CH3)0C,H6 -CH,- oil 7 -CH,- c,h6 c,h6 -ch,och3 -CH,- oil d) 5-hvdroxv-4-(4-methvlpiperazinvlmethvl)-1.3-benzodioxole Aqueous HCI (300 ml, 0.5 N) was added to a stirred solution of 5(1-ethoxyethoxy)-4-(4-methylpiperazinylmethyl)-1,3-benzodioxole (16.0 g, 49.7 mmol) in 2-propanol (300 ml) at room temperature, and stirring was continued for 15 minutes. The solution was extracted with diethyl ether, the aqueous layer was neutralised (pH = 7) by adding aqueous NaOH(2N), and the water layer was evaporated in vacuo. The residue was extracted with diethyl ether (3 times). The combined organic layers were dried over Na2SO4, filtered and evaporated in vacuo to yield a crude oil (9.6 g). This oil was purified by flash chromatography (eluent: acetone/ethyl acetate = 1/1 (v/v)) to yield 5-hydroxy-4-(4 methylpiperazinylmethyl) -1 ,3-benzodioxole (7.6 g, 61% yield, compound no. 8) as a solid, m.p. 85-87°C.
In a similar manner the compounds of formula 5 wherein R,-R4 and Z have the meanings indicated in Table B were prepared.
TABLE B Comp. no. R ί 4- R 2 R3 ί 4-) R< z m.p. (°C) 9 10 1 1 -CH,- -CH,- -CH,- c,h6 c,h6 -6- - -CH,- -CH,- CH,- oil oil 1 90 DIR 0482 e) 4-(4-methvlpiperazinylmethvl)-5-phenvlpropoxv-1.3benzodioxole .2HCI) 3-Phenylpropyl bromide (1.81 g, 9.1 mmol) was added to a mixture of5-hydroxy-4-(4-methylpiperazinylmethyl)-1,3-benzodioxole(1.9 g, 7.6 mmol), sodium iodide (0.1 g, 0.7 mmol) and potassium tertbutoxide (1.12 g, 9.9 mmol) in DMSO (30 ml). The stirred mixture was heated at 80°C for two hours. Thereafter, the mixture was allowed to attain room temperature, water was added and the resulting solution was extracted with diethyl ether (3 times), the combined ether extracts were washed with 2N aqueous NaOH and water respectively, and dried over Na2SO4. Gaseous HCl was added and the formed precipitate was filtered. This precipitate was recrystallised from 2-propanol/methanol = 9/1 (v/v) to yield 4-(4methylpiperazinylmethyl)-5-phenylpropoxy-1,3-benzodioxole. 2HCI (2.9 g, 87% yield; compound no. 12) as a white solid, m.p. 223225°C.
In a similar manner the compounds of formula 1A, wherein R,-R5 and Z have the meanings indicated in Table C were prepared.
TABLE C Comp. no. R, + R 2 R3 (+) R. R„ Z salt m.p. (°C) 1 3 -ch,- c2h6 c2h6n‘C5H,, -CH2- HBr 1 30-2 1 4 -CH2- c2h5 c2h6 -ch2- HBr 145-7 1 5 -CH,- -2)„- n- C3H ) ch2- HCl 134-6 1 6 -CHj- •2)6- n-C6H,, CH2- HCl 1 42-4 1 7 -ch2- -2)6- CH2C„H5 -ch2- free base 100-2 18 -ch2- (CH2)6- (CHjIgCgHg -ch2- HBr 129-33 1 9 -ch2- -1CH2)2N(CH3)(CH2)2- n - C 4 H q -ch2- 2HCI 208 dec 20 -CH,- (CH2|,N(CH3)|CH,|,- CH2CeH6 -ch2- 2HCI 100-5 dec 2 1 -ch2- |CH,),N|CH3)|CH,|,- CH2-2-CI-CeH4 -CHj- 2HCI 172-5 22 •CH,- (CH2)2N((CH2)2CH3)(CH2)2- n-C4HB -CHj- 2HCI 210-12 23 -ch2- -(CH2)2N((CH2)2CH3)(CH2)2- CH2C6H5 -CHj- 2HCI 219-21 24 -(CH2)j- -(CH2)2N(CH3)(CH2)2- (CH2)3CeHb -CHj- 2HCI 198-201 DIR 0482 Example II a) 4-hvdroxy-5-(4-propvlpiperazinylmethvl)-1.3-benzodioxole Aqueous formaldehyde (37%; 3.67 g, 45.3 mmol) was added dropwise to a stirred solution of 4'hydroxy-1,3-benzodioxole (5.2 g, 37.8 mmol) and N-propylpiperazine (5.8 g, 45.3 mmol) in acetonitrile (25 ml). The reaction mixture was stirred at room temperature for one hour and evaporated in vacuo. The remaining oil (13.0 g) was purified chromatographically (with ethylacetate/methanol = 9/1 (v/v) as an eluent to give 4-hydroxy5-(4-propylpiperazinylmethyl)-1,3-benzodioxole (5.9 g, 56% yield; compound no. 25), m.p. 115-117°C.
In a similar manner the compounds of formula 6 wherein Z and R ,-R4 have the meanings indicated in Table D were prepared.
TABLE D Comp. no. R i + R 2 R3 <+) R* z m.p. (°C) 26 -ch2- CjH6 c2h6 -ch2- oil 27 CH,- -2)6- CH,- 1 56-8 28 CH,- -(CH2)2N(CH3)(CH2)2- -ch2- 118-20 b) 4-butoxv-5-(4-propvlpiperazinvlmethvl)-1,3-benzodioxole .2HCI Butyl bromide (1.71 g, 12.5 mmol) was added to a mixture of 5-(4propylpiperazinylmethyl)-4-hydroxy-1,3-benzodioxole (2.9 g, 10.4 mmol), sodium iodide (0.1 g, 0.7 mmol) and potassium tert-butoxide (1.53 g, 13.5 mmol) in DMSO (30 ml). The stirred mixture was heated at 80°C for 2 hours. Thereafter, the mixture was allowed to attain room temperature, water was added and the resulting solution was extracted with diethyl ether (3 times). The combined ether extracts were washed with 2N aqueous NaOH and water, respectively. The combined ether extracts were extracted twice with HCI (10 ml of a 10% aqueous solution). The combined aqueous layers were extracted with diethyl ether and made alkaline (pH = 13) by addition of NaOH (25 ml of a 50% aqueous solution). 1 DIR 0482 The resulting solution was extracted twice with diethyl ether. The combined ether extracts were dried over Na2SO4 and filtered. The filtrate was saturated with gaseous hydrogen chloride and evaporated in vacuo to yield 4-butoxy-5-(4-propylpi perazinyl5 methyl)-1 ,3-benzodioxole.2HCI (2.04 g, 48% yield; compound no. 29) as a pure white solid, m.p. 245°C (decomposition).
In a similar manner the compounds of formula 1 B wherein R,-R5 and Z have the meanings indicated in Table E were prepared.
TABLE E Comp. no. R ! + R 2 r3 (+) r4 r6 Z salt m.p. (°C) 30 -CHj- c2h6 c2h6 n-C6Hn -ch2- HCI 103-5 31 -ch2- C2H5 C 2H5 (CH2)3CeH6 -ch2- HCI 1 1 6-8 32 -ch2- -2)6- n-CsH,, -ch2- HCI 168-70 33 -ch2- (ch2)6- CH2CeH5 -ch2- HCI 205-8 34 -ch2- (CH2)2N|CH3)(CH2)2- n-C4He -ch2- 2HCI 198-201 35 -ch2- (CH2)2N(CH3)(CH2)2- CH2C„H5 CHj- 2HCI 262 dec. 36 -ch2- (CH2)2N(CH3)(CH2)2- CH2-2-CI-CeH4 -ch2- 2HCI 257 dec. 37 -ch2- -ICH2)2N(CH3KCH2)2- (CH2)3CeH6 -ch2- 2HCI 247 dec. 38 -ch2- (CH2)2N((CH2)2CH3)(CH2)2- CH2CeH6 -ch2- 2HCI 242 dec.
DIR 0482
Claims (8)
1. Compounds of the formulae 1A and 1B 10 (1A) (1B) wherein: -R, + R 2 together form an alkylene group having 1-3 C-atoms which may be substituted with one or more alkyl group(s) having 1 -3 C-atoms; 15 -Z is methylene optionally substituted with one alkyl group having 1-3 C-atoms, or with one phenylalkyl group with 1-3 C-atoms in the alkyl group, which phenyl group may be substituted with a group (R e ) p wherein R e is halogen, hydroxy, alkyl or hydroxyalkyl having 1-5 C-atoms, alkoxy having 1-3 20 C-atoms, S-alkyl, S(O)-alkyl or S(O) 2 ~all 2 NKR or a carbalkoxy group COOR wherein R is alkyl having 1-4 C-atoms, the group COOH, 25 SO 3 H,CONH 2 , the amidino group or cyano group, and p has the value 0-3; -R 3 and R 4 independent of each other represent hydrogen, alkyl having 1-10 C-atoms, alkenyl or alkynyl having 3-10 Catoms, cycloalkyl having 3-8 C-atoms, cycloalkyl- alkyl 30 having 3-8 ring atoms and 1-5 C-atoms in the alkyl group, phenylalkyl or heteroaryl-alkyl having 1-5 C- atoms in the alkyl group, phenylalkenyl, heteroaryl - alkenyl, phenylalkynyl or heteroaryl-alkynyl group having 3-5 C-atoms in the alkenyl group or alkynyl group, which groups R 3 and R 4 may be 35 substituted with a group (R e ) p wherein R 6 and p have the above mentioned meanings, or wherein R 3 + R 4 together with the nitrogen atom form a saturated or unsaturated DIR 0482 heterocyclic group of 5-7 ring atoms, which may contain a second hetero-atom from the group consisting of oxygen, sulphur and nitrogen, which ring may be substituted with a group (R 6 )p wherein R e and p have the above mentioned meanings, or with phenylalkyl, h e t e r o a r y I - a I k y I, phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl having at most 3 C-atoms in the alkyl, alkenyl or alkynyl part, which groups may be substituted with a group (R e ) p wherein R e and p have the above-mentioned meanings, or which ring may be annelated with a phenylgroup; -R 5 is alkyl having 1-12 C-atoms, alkenyl or alkynyl having 3-12 C-atoms, cycioalkyl having 3-8 C-atoms, cycloalkyl-alkyl having 3-8 ring atoms and 1-5 C-atoms in the alkyl group, phenylalkyl or heteroaryl-alkyl having 1 - 5 C-atoms in the alkyl sub-group, phenylalkenyl, heteroaryl-alkenyl, phenylalkynyl or heteroaryl-alkynyl having 3-5 C-atoms in the alkenyl subgroup or alkynyl sub-group, which groups may be substituted with a group (R e ) p , wherein R 6 and p have the abovementioned meanings, and which alkyl sub-groups, alkenyl sub-groups and alkynyl sub-groups may contain a group -O-, -S- or CO, or a pharmacologically acceptable salt thereof.
2. A method of preparing alkylenedioxyphenyl ether derivatives, characterized in that compounds having formula 1 A or 1B, wherein Z and R,-R 5 have the meanings given in claim 1 are prepared by reacting a compound having formula 5 or 6 (5) (6) with a compound of the formula R 5 -X wherein R 5 has the meaning given in claim 1 and X is a leaving group. DIR 0482 given in claim 1 and X is a leaving group.
3. Compositions having anti-ischaemic, memory enhancing and anti-convulsive activity which comprise at least one compound as claimed in claim 1 as active component.
4. A method of preparing compositions as claimed in claim 3, characterized in that a compound of formula 1A or 1B wherein the symbols have the meaning mentioned in claim 1 , or a salt thereof, is brought into a form suitable for administration.
5. A method of treating ischaemia, impaired memory or epilepsy, characterized in that a compound according to claim 1 is used.
6. A composition as defined in Claim 1, substantially as described herein by way of example.
7. A method of preparing alkylenedioxyphenyl ether derivatives, substantially as described herein by way of example.
8. A composition prepared by the method of any of Claims 2, 4 and 7.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE920840A IE920840A1 (en) | 1992-03-16 | 1992-03-16 | Alkylenedioxyphenyl ether derivatives having anti-ischaemic,¹memory enhancing and anti-convulsive activity |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IE920840A IE920840A1 (en) | 1992-03-16 | 1992-03-16 | Alkylenedioxyphenyl ether derivatives having anti-ischaemic,¹memory enhancing and anti-convulsive activity |
Publications (1)
Publication Number | Publication Date |
---|---|
IE920840A1 true IE920840A1 (en) | 1992-09-23 |
Family
ID=11039588
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE920840A IE920840A1 (en) | 1992-03-16 | 1992-03-16 | Alkylenedioxyphenyl ether derivatives having anti-ischaemic,¹memory enhancing and anti-convulsive activity |
Country Status (1)
Country | Link |
---|---|
IE (1) | IE920840A1 (en) |
-
1992
- 1992-03-16 IE IE920840A patent/IE920840A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2867151B2 (en) | Biperidinyl benzimidazoles | |
EA003272B1 (en) | Derivatives of dihydro- and tetrahydroquinoline, process for preparing them and pharmaceutical compositions containing them | |
IE58916B1 (en) | New pharmaceutical compositions having anti-psychotic properties | |
WO2007129111A1 (en) | Diazepine derivatives as 5-ht2a antagonists | |
CA2004670A1 (en) | Anxiolytically active piperazine derivatives | |
EP0330353B1 (en) | Tetrazole excitatory amino acid receptor antagonists | |
AU641585B2 (en) | 2-substituted quinolines, process for their preparation and their use in medicaments | |
FR2589152A1 (en) | PYRIDINE-3-CARBOXAMIDE DERIVATIVES AND THEIR APPLICATION AS INHIBITORS OF PLANT GROWTH | |
US5744605A (en) | Intermediates in the synthesis of (+) camptothecin and related compounds and synthesis thereof | |
EP0255710A2 (en) | 1,4-Dihydropyridine derivatives with calcium agonist and alpha-1-antagonist activity | |
US5281595A (en) | Alkylenedioxyphenyl ether derivatives having anti-ischaemic, memory enhancing and anti-convulsive activity | |
US6211371B1 (en) | Intermediates in the synthesis of camptothecin and related compounds and synthesis thereof | |
IE920840A1 (en) | Alkylenedioxyphenyl ether derivatives having anti-ischaemic,¹memory enhancing and anti-convulsive activity | |
CA2084541A1 (en) | Piperidylmethyl-substituted chroman derivatives | |
CZ332995A3 (en) | The use of 5-acyl-1,4-dihydropyridines, 5-acyl-1,4-dihydropyridines per se, process of their preparation and pharmaceutical compositions containing thereof | |
EP0420327A1 (en) | Phenylalkyl amine derivatives having anti-ischaemic activity | |
EP1603899A1 (en) | Heterocyclic urea derivatives for the treatment of pain | |
HUT70041A (en) | 2-substituted quinolylmethoxy-phenylacetic acid derivatives, pharmaceutical compositions comprising them and the process for preparing thereof | |
US6252079B1 (en) | Intermediates in the synthesis of camptothecin and related compounds and synthesis thereof | |
DE3302814A1 (en) | NEW ALLYLAMINES, METHOD FOR THEIR PRODUCTION AND THEIR USE | |
US5356891A (en) | Phenylalkyl amine derivatives having anti-ischaemic activity | |
JPH03204881A (en) | Novel synthesis of oxazolopyridine derivative | |
JPH0597843A (en) | Alkylene dioxyphenyl ether derivative having anti-ischemic, mnemonic and anti-convulsive activities | |
CA2473790C (en) | 1,4-dihydropyridine and pyridine compounds as calcium channel blockers | |
CZ286192A3 (en) | Dihydropyridines substituted by indolesulfonamides, process of their preparation and their use in medicaments |